<--- Back to Details
First PageDocument Content
Neurochemistry / Medicine / Clinical medicine / Complement deficiency / RTT / Sodium channel blockers / Euphoriants / Calcium channel blockers / Hereditary angioedema / Syringe / Angioedema / Ketamine
Date: 2016-07-27 08:19:27
Neurochemistry
Medicine
Clinical medicine
Complement deficiency
RTT
Sodium channel blockers
Euphoriants
Calcium channel blockers
Hereditary angioedema
Syringe
Angioedema
Ketamine

Microsoft Word - CINRYZE.Product Monographdoc

Add to Reading List

Source URL: www.shirecanada.com

Download Document from Source Website

File Size: 166,30 KB

Share Document on Facebook

Similar Documents

[Product Monograph Template - Schedule D]

[Product Monograph Template - Schedule D]

DocID: 1qWQL - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

Microsoft Word - CINRYZE.Product Monographdoc

Microsoft Word - CINRYZE.Product Monographdoc

DocID: 1qE2h - View Document

Microsoft Word - FIRAZYR.Product Monographdoc

Microsoft Word - FIRAZYR.Product Monographdoc

DocID: 1qA9x - View Document

Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop

Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop

DocID: 1pVHk - View Document